Previous 10 | Next 10 |
MALVERN, Pa., May 23, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company will present at the 2023 BIO...
2023-05-05 15:00:35 ET Image source: The Motley Fool. Ocugen (NASDAQ: OCGN) Q1 2023 Earnings Call May 05, 2023 , 8:30 a.m. ET Operator Continue reading For further details see: Ocugen (OCGN) Q1 2023 Earnings Call Transcript
2023-05-05 12:17:09 ET Start Time: 08:30 End Time: 09:05 Ocugen, Inc. (OCGN) Q1 2023 Earnings Conference Call May 05, 2023, 08:30 AM ET Company Participants Shankar Musunuri - Chairman, CEO and Co-Founder Quan Vu - CFO and Chief Business Officer Sharon Ch...
2023-05-04 12:44:23 ET Ocugen ( NASDAQ: OCGN ) is scheduled to announce Q1 earnings results on Friday, May 5th, before market open. The consensus EPS Estimate is -$0.11 and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 2 upward...
MALVERN, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and liv...
2023-04-27 08:52:21 ET The U.S. FDA granted orphan drug designation (ODD) to Ocugen's ( NASDAQ: OCGN ) gene therapy OCU410ST (AAV5- hRORA) to treat certain vision disorders. The ODD was given for treating ABCA4-associated retinopathies, including Stargardt, Retinitis Pigme...
MALVERN, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the FDA has granted Orphan Drug Design...
2023-04-26 09:06:43 ET Summary Today, we revisit Ocugen for the first time since the summer of 2022. The stock has withered since then but the stock picked up an analyst upgrade in March and posted encouraging interim trial data in April. Possible signs of a turnaround for its...
MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Sh...
MALVERN, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company will present on its innova...
News, Short Squeeze, Breakout and More Instantly...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...